Fasedienol

Summary

Fasedienol (CHEMBL5095042) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including social phobia and adjustment disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 3
• Chemistry: 272.4 Da · C19H28O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095042
Name	Fasedienol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9925482
Molecular formula	C19H28O
Molecular weight	272.4
InChIKey	NYVFCEPOUVGTNP-DYKIIFRCSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CCC4=C[C@H](CC[C@]34C)O

IUPAC name: (3S,8S,9S,10R,13R,14S)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol

Also known as: Aloradine, Fasedienol, Ph94b, PH94B, FASEDIENOL

Patent coverage: 39 distinct patent families (77 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
social phobia	3	MONDO:0001247	EFO:1001917
adjustment disorder	2	MONDO:0003265	MONDO:0003265
anxiety disorder	2	MONDO:0005618	EFO:0006788
anxiety	1	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02622958	PHASE3	COMPLETED	Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
NCT05030350	PHASE3	TERMINATED	Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
NCT04404192	PHASE2	COMPLETED	PH94B in the Treatment of Adjustment Disorder With Anxiety

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).